Loading insider details...
Beta
Latest Form 4 (Jun 17, 2026): Grant/Award of 3,135 APRE shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 17, 2026 | Aprea Therapeutics, Inc. (APRE) | Grant/Award | 3,135 | n/a |
| Jun 3, 2026 | ADC Therapeutics SA (ADCT) | Grant/Award | 45,000 | n/a |
| Jun 17, 2025 | ADC Therapeutics SA (ADCT) | Tax Withholding | 12,600 | $45.1K |
| Jun 9, 2025 | Aprea Therapeutics, Inc. (APRE) | Grant/Award | 1,045 | n/a |
| Jun 5, 2025 | ADC Therapeutics SA (ADCT) | Grant/Award | 40,000 | n/a |
| Jun 19, 2024 | ADC Therapeutics SA (ADCT) | Sale | 6,995 | $20.2K |
| Jun 14, 2024 | ADC Therapeutics SA (ADCT) | Grant/Award | 40,000 | n/a |
| Aug 25, 2023 | Aprea Therapeutics, Inc. (APRE) | Grant/Award | 12,500 | n/a |
| May 9, 2023 | HALOZYME THERAPEUTICS, INC. (HALO) | Grant/Award | 8,065 | n/a |
| May 7, 2022 | HALOZYME THERAPEUTICS, INC. (HALO) | Grant/Award | 6,206 | n/a |